Advice

following a full submission assessed under the orphan medicine process:

lutetium (177Lu) oxodotreotide (Lutathera®) is accepted for use within NHSScotland.

Indication under review: for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.

In an open-label, phase III study, lutetium (177Lu) oxodotreotide significantly improved progression-free survival compared with a high dose somatostatin analogue in patients with progressive midgut neuroendocrine tumours.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.

Download full details334KB (PDF)

Download

Medicine details

Medicine name:
lutetium 177Lu oxodotreotide (Lutathera)
SMC ID:
1337/18
Indication:
Unresectable or metastatic, progressive, well differentiated (G1 and G2) somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours in adults.
Pharmaceutical company
Advanced Accelerator Applications
BNF chapter
Malignant disease and immunosuppression
Submission type
Full submission
Status
Accepted
Date advice published:
09 July 2018